Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022 Lynch: Aetna expects to add at least 100K members in ACA exchange plans for 2022 After a phase of slower growth, Novo Nordisk sees the fruits of its Wegovy and Rybelsus launches, CEO says CMS finalizes fee hikes for hospital price transparency requirements Turning CAR-T tech against solid tumors by targeting protein fragments in cancer cells Boston Scientific wins $20M patent infringement case against Nevro over spinal cord stimulators Merck will support Saudi Arabia effort to build biologics manufacturing operations Heru adds 3 more diagnostics to VR headset-based vision testing platform Incyte investigates all batches of new eczema cream Opzelura after reports of 'texture problem' PhaseBio’s Brilinta reversal agent wins midstage test as biotech awaits key data on emergency patients Centene selling off majority stake in U.S. Medical Management Cara chief hands keys to former LEO head Posner, months after first approval in its 17-year history Allara launches at-home hormone test for diagnosing polycystic ovary syndrome Featured Story | By Nick Paul Taylor Pfizer’s vision for a banner 2022 in gene therapies is over. Having previously expected to post interim data on a trio of phase 3 programs next year, Pfizer has now delayed all the readouts, setting back its plans in hemophilia and Duchenne muscular dystrophy. read more |
| |
|---|
|
Top Stories By Paige Minemyer CVS Health beat Wall Street forecasts on both earnings and revenue for the third quarter of 2021. read more By Eric Sagonowsky As Novo worked to advance its suite of next-gen medicines back in 2016 and 2017, the company was in a phase of "relatively low growth," CEO Lars Fruergaard Jørgensen acknowledges. Now, thanks to new launches, things have changed. read more By Paige Minemyer Beginning Jan. 1, the Biden administration will increase the penalty for certain hospitals that are not in compliance with its price transparency requirements. read more By Angus Liu A University of Pennsylvania team has developed a new type of engineered immune cell called “peptide-centric” CAR-T that's designed to shrink solid tumors by targeting proteins inside cancer cells. CAR-T cells developed with the technology eradicated neuroblastoma in mouse models and could move into human trials in 2022 or 2023. read more By Andrea Park One major piece of the long-lasting and multifaceted legal battle between Boston Scientific and Nevro has finally come to a close. read more By Joseph Keenan Merck has signed on to help SaudiVax of Saudi Arabia design and construct a multimodality biologics manufacturing facility as part of the country’s efforts to provide a more localized production infrastructure for the Middle East, Northern Africa region. read more By Andrea Park After beginning the commercial launch of its re:Vive gamified vision testing platform in August, Heru has already debuted an updated version of the technology. read more By Angus Liu Incyte has only taken the first step in its rollout of topical atopic dermatitis drug Opzelura, but it has already hit a manufacturing problem that that threatens to derail the key launch. It has received three related complaints of texture problems related to the drug. read more By Annalee Armstrong PhaseBio’s Brilinta reversal drug has scored a mid-stage win without any adverse events or blood clot issues, layering on the data to support the therapy that’s already pushing through phase 3. read more By Paige Minemyer Centene will sell off its majority stake in home health company U.S. Medical Management, the insurer announced Wednesday. read more By Kyle LaHucik It took 17 years to get its first FDA greenlight. Three months later, Cara Therapeutics founding CEO Derek Chalmers exits the top perch as LEO Pharma's U.S. CEO and president enters the role. read more By Conor Hale After launching a virtual care platform aimed at PCOS this past summer, Allara is now debuting a diagnostic tool to sift through multiple hormone biomarkers. It hopes to reduce the diagnosis time from an average of three years to as many days. read more | 